Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02649608 · ClinicalTrials.gov registry record · Phase 1
An Exploratory Study Investigating Safety, Tolerability and Pharmacokinetics of Ascending Doses of Lu AE04621 in Parkinson Disease Patients
A Phase 1 study, sponsored by H. Lundbeck A/S.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT02649608 is a Phase 1 study that has completed, run by H. Lundbeck A/S. The registered enrollment target is 15 participants.
The verdict
NCT02649608, a Phase 1 study, has completed, sponsored by H. Lundbeck A/S.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
To evaluate the safety, tolerability, pharmacokinetics, and efficacy of the Lu AE04621 and metabolite after ascending oral doses of Lu AE04621 in patients with Parkinson's Disease.
Interventions
- DRUG 0.04 mg Lu AE04621
- DRUG 0.08 mg Lu AE04621
- DRUG 0.2 mg Lu AE04621
- DRUG 0.4 mg Lu AE04621
- DRUG 0.6 mg Lu AE04621
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2016-01 |
| Est. Completion | 2016-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02649608
The ClinicalTrials.gov registry entry for NCT02649608 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is H. Lundbeck A/S, which has 72 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which 0.04 mg Lu AE04621 is the first listed.
NCT02649608 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02649608 about?
NCT02649608 is a clinical study titled "An Exploratory Study Investigating Safety, Tolerability and Pharmacokinetics of Ascending Doses of Lu AE04621 in Parkinson Disease Patients". To evaluate the safety, tolerability, pharmacokinetics, and efficacy of the Lu AE04621 and metabolite after ascending oral doses of Lu AE04621 in patients with Parkinson's Disease.
What is the current status of trial NCT02649608?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2016-01. Estimated completion is 2016-12.
What interventions are being tested in trial NCT02649608?
The interventions under investigation include: 0.04 mg Lu AE04621 (DRUG), 0.08 mg Lu AE04621 (DRUG), 0.2 mg Lu AE04621 (DRUG), 0.4 mg Lu AE04621 (DRUG), 0.6 mg Lu AE04621 (DRUG).
Who is sponsoring clinical trial NCT02649608?
This trial is sponsored by H. Lundbeck A/S, which has 72 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.